To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Already have an account?
MorphoSys and Pfizer’s Antibody Development Deal Expanded for Three Years
Read time: Less than a minute
MorphoSys
has announced that it has expanded its collaboration with
Pfizer
for the development of antibody therapeutics by three years.
The agreement builds upon a deal struck in 2003 scheduled to end in 2008. The new deal extends the collaboration to 2011 and includes a one-off payment from Pfizer, MorphoSys said.
Under the agreement, MorphoSys, based in Martinsried, Germany, will use its HuCAL Gold human combinatory antibody library to generate therapeutic antibodies against targets supplied by Pfizer, which Pfizer will then take to preclinical and clinical trials.
MorphoSys said the agreement offers potential royalties and milestone payments from resulting product sales.
Financial terms of the agreement were not released.
The agreement builds upon a deal struck in 2003 scheduled to end in 2008. The new deal extends the collaboration to 2011 and includes a one-off payment from Pfizer, MorphoSys said.
Under the agreement, MorphoSys, based in Martinsried, Germany, will use its HuCAL Gold human combinatory antibody library to generate therapeutic antibodies against targets supplied by Pfizer, which Pfizer will then take to preclinical and clinical trials.
MorphoSys said the agreement offers potential royalties and milestone payments from resulting product sales.
Financial terms of the agreement were not released.
